Transplantation: To convert or not to convert: lessons from the CONVERT trial.
In participants of the CONVERT trial, which enrolled recipients of kidney transplants, conversion of immunosuppressive therapy from calcineurin inhibitors to sirolimus did not improve renal function. More importantly, the intervention was detrimental among patients with impaired kidney function and/or proteinuria. Sirolimus conversion resulted, however, in lower rates of malignancy.
Bunnapradist
Suphamai
S
Vincenti
Flavio
F
D065095:Calcineurin Inhibitors; D051799:Delayed Graft Function / Q000517:prevention & control*; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D007680:Kidney Neoplasms / Q000453:epidemiology / Q000517:prevention & control; D016030:Kidney Transplantation; D011507:Proteinuria / Q000517:prevention & control; D020123:Sirolimus / Q000627:therapeutic use*
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D020123:Sirolimus